J&J (JNJ) adds another approval request to the FDA for Xarelto, applying to use the blood...

|By:, SA News Editor

J&J (JNJ) adds another approval request to the FDA for Xarelto, applying to use the blood thinner for helping to reduce the risk of blood clots developing in heart stents in patients with acute coronary syndrome. Xarelto is already authorized for certain use cases.